We are live on ! Find out more
SRPT icon

Sarepta Therapeutics

186 hedge funds and large institutions have $2.59B invested in Sarepta Therapeutics in 2016 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 54 increasing their positions, 52 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

292% more capital invested

Capital invested by funds: $661M → $2.59B (+$1.93B)

267% more funds holding in top 10

Funds holding in top 10: 311 (+8)

158% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 24

26% more funds holding

Funds holding: 148186 (+38)

4% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 52

33% less call options, than puts

Call options by funds: $524M | Put options by funds: $780M

Holders
186
Holders Change
+38
Holders Change %
+25.68%
% of All Funds
4.96%
Holding in Top 10
11
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+266.67%
% of All Funds
0.29%
New
62
Increased
54
Reduced
52
Closed
24
Calls
$524M
Puts
$780M
Net Calls
-$256M
Net Calls Change
-$90.9M

SRPT Hedge Fund Activity: Q3 2016 in Review

186 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2016, worth a combined $2.59B — up 292% from $661M a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new SRPT positions and 24 closed out — a net gain of 38 holders — while 54 added to existing stakes and 52 trimmed.

The largest buyer was Tourbillon Capital Partners, opening a new position worth an estimated $51.8M. The largest seller was Group One Trading, exiting entirely with an estimated $17.3M sold.

  • 186 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2016, up from 148 in Q2 2016.
  • Funds reported $2.59B of Sarepta Therapeutics stock for Q3 2016, up 292% quarter-over-quarter.
  • 62 funds opened new Sarepta Therapeutics positions in Q3 2016 and 24 closed out, a net change of +38 holders.
  • The largest Sarepta Therapeutics buyer in Q3 2016 was Tourbillon Capital Partners, an estimated $51.8M added.
  • The largest Sarepta Therapeutics seller in Q3 2016 was Group One Trading, an estimated $17.3M sold.

Based on aggregated 13F filings for Q3 2016.